As we said earlier today, Pfizer continues to shine in the spotlight after years of the pandemic. Now, it’s been reported that a new booster shot from the company has just been approved by a Swiss drug regulator. Check out the latest reports about this issue below.
Swiss drug regulator approves Pfizer covid booster shot
It’s been just reported that the Swiss drugs regulator Swissmedic said on Monday it had temporarily approved Pfizer’s COVID-19 booster shot targeting the original and BA.1 Omicron coronavirus variants, according to the Reuters press agency.
The same notes reveal that Swissmedic added that the data currently available to it was not yet sufficient to make a decision on Pfizer’s bivalent booster vaccine targeting the BA.4 and BA.5 Omicron variants.
Pfizer’s vaccines and boosters have been making headlines this year and the one before, due to the controversial nature of the vaccines.
Pfizer in the news
Now, the exec of Pfizer has a few things to say regarding some allegations about the distribution of the vaccine in Europe. Check out more details below.
It’s been just reported that he has “categorically” ruled out that the pharma giant’s chief executive agreed on the European COVID-19 contract via mobile phone text messages.
According to fresh reports, the executive was involved in negotiating a covid vaccine bulk supply agreement with the European Commission.
“The European Commission signed a third contract with BioNTech SE and Pfizer for an additional 1.8 billion doses of its COVID-19 vaccine,” Benzinga’s official website notes.
According to the same reports, a new agreement will initially supply 900 million doses of the vaccine with an option to request up to an additional 900 million doses.
Controversial Pfizer vaccine issues
The vaccine released by Pfizer has been surrounded by controversy since the beginning. Back in March, we revealed that the Pfizer covid vaccine should have been removed from the market following the first deaths were reported, according to an expert cardiologist. Check out dr. Peter McCullough’s tweet below.
Pfizer/BNT had duty to pull it off the market when the death reports started to come in shortly after its ill-fated release on the public market. Many companies would have done it in January or February of 2021 at the very latest before more recipients lost their lives. pic.twitter.com/zcWnn2rZAK
— Peter McCullough, MD MPH (@P_McCulloughMD) April 13, 2022
Stay tuned for more news.
